Update on the management of the liver transplant patient

Current Opinion in Gastroenterology

Volumn 31, Issue 3, 2015, Pages 224-232

  Kwong, Allison J ^a   Fix, Oren K ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

Author keywords

allocation; liver transplantation; model for end stage liver disease; updates; waiting list

Indexed keywords

ALBUMIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; SODIUM;

ACUTE ON CHRONIC LIVER FAILURE; ALCOHOL LIVER DISEASE; ASCITES; BRAIN DISEASE; CONCENTRATION PROCESS; DISEASE CLASSIFICATION; END STAGE LIVER DISEASE; FUNCTIONAL STATUS; HEALTH CARE ACCESS; HEALTH DISPARITY; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER GRAFT; MANAGED CARE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; NONALCOHOLIC FATTY LIVER; NUTRITIONAL SUPPORT; OBESITY; OVERALL SURVIVAL; PREVALENCE; PROGNOSIS; REVIEW; SARCOPENIA; SOCIAL STATUS; SODIUM BLOOD LEVEL; SURVIVAL RATE; TREATMENT INDICATION; VARICOSIS; ADULT; AGED; BLOOD; COMORBIDITY; FRAIL ELDERLY; HOSPITAL ADMISSION; LIVER TRANSPLANTATION; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SELECTION; PROCEDURES; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; TIME; TRANSPLANTATION;

ADULT; AGED; ASCITES; COMORBIDITY; END STAGE LIVER DISEASE; EVEROLIMUS; FRAIL ELDERLY; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MIDDLE AGED; OBESITY; PATIENT SELECTION; PROGNOSIS; SARCOPENIA; SEVERITY OF ILLNESS INDEX; SODIUM; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; WAITING LISTS;

EID: 84928569868     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000173     Document Type: Review

References (92)

1. Kim WR, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 Annual Data Report: liver. Am J Transplant 2014; 14 (Suppl 1):69-96.
2. Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57:675-688.
3. Singal AK, Guturu P, Hmoud B, et al. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. Transplantation 2013; 95:755-760.
4. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141:1249-1253.
5. Freeman RB, Wiesner RH, Edwards E, et al. Results of the first year of the new liver allocation plan. Liver Transpl 2004; 10:7-15.
6. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359:1018-1026.
7. Porrett PM, Baranov E, Ter Horst M. Serum hypoalbuminemia predicts late mortality on the liver transplant waiting list. Transplantation 2015; 99:158-163.
8. Myers RP, Shaheen AA, Faris P, et al. Revision of MELD to include serum albumin improves prediction of mortality on the liver transplant waiting list. PLoS One 2013; 8:e51926.
9. Myers RP, Tandon P, Ney M, et al. Validation of the five-variable Model for Endstage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list. Liver Int 2014; 34:1176-1183.
10. Biselli M, Dall'agata M, Gramenzi A, et al. A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. Liver Int 2015; 35:184-191.
11. Wedd J, Bambha KM, Stotts M, et al. Stage of cirrhosis predicts the risk of liver-related death in patients with low Model for End-Stage Liver Disease scores and cirrhosis awaiting liver transplantation. Liver Transpl 2014; 20:1193-1201.
12. Finkenstedt A, Nachbaur K, Zoller H, et al. Acute-on-chronic liver failure: excellent outcomes after liver transplantation but high mortality on the wait list. Liver Transpl 2013; 19:879-886.
13. Jalan R, Pavesi M, Saliba F, et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol 2014. [Epub ahead of print]
14. Jara M, Malinowski M, Luttgert K, et al. Prognostic value of enzymatic liver function for the estimation of short-term survival of liver transplant candidates: A prospective study with the LiMAx test. Transpl Int 2015; 28:52-58.
15. Malinowski M, Jara M, Luttgert K, et al. Enzymatic liver function capacity correlates with disease severity of patients with liver cirrhosis: A study with the LiMAx test. Dig Dis Sci 2014; 59:2983-2991.
16. Nair S, Cohen DB, Cohen MP, et al. Postoperative morbidity, mortality, costs, and long-term survival in severely obese patients undergoing orthotopic liver transplantation. Am J Gastroenterol 2001; 96:842-845.
17. Dick AA, Spitzer AL, Seifert CF, et al. Liver transplantation at the extremes of the body mass index. Liver Transpl 2009; 15:968-977.
18. Orci LA, Majno PE, Berney T, et al. The impact of wait list body mass index changes on the outcome after liver transplantation. Transpl Int 2013; 26: 170-176.
19. Singhal A, Wilson GC, Wima K, et al. Impact of recipient morbid obesity on outcomes after liver transplantation. Transpl Int 2015; 28:148-155.
20. Hakeem AR, Cockbain AJ, Raza SS, et al. Increased morbidity in overweight and obese liver transplant recipients: A single-center experience of 1325 patients from the United Kingdom. Liver Transpl 2013; 19:551-562.
21. Heimbach JK, Watt KD, Poterucha JJ, et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant 2013; 13:363-368.
22. Al-Nowaylati AR, Al-Haddad BJ, Dorman RB, et al. Gastric bypass after liver transplantation. Liver Transpl 2013; 19:1324-1329.
23. Organ Procurement and Transplantation Network. Data. 2014; Available at: http://optn.transplant.hrsa.gov/converge/data/. [Accessed 1 December 214]
24. Sharpton SR, Feng S, Hameed B, et al. Combined effects of recipient age and model for end-stage liver disease score on liver transplantation outcomes. Transplantation 2014; 98:557-562.
25. Malinis MF, Chen S, Allore HG, Quagliarello VJ. Outcomes among older adult liver transplantation recipients in the model of end stage liver disease (MELD) era. Ann Transplant 2014; 19:478-487.
26. Wilson GC, Quillin RC, Wima K, et al. Is liver transplantation safe and effective in elderly (>/1/470 years) recipients? A case-controlled analysis. HPB (Oxford) 2014; 16:1088-1094.
27. Kim J, Ko ME, Nelson RA, et al. Increasing age and survival after orthotopic liver transplantation for patients with hepatocellular cancer. J Am Coll Surg 2014; 218:431-438.
28. Lai JC, Feng S, Terrault NA, et al. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant 2014; 14:1870-1879.
29. Ow MM, Erasmus P, Minto G, et al. Impaired functional capacity in potential liver transplant candidates predicts short-term mortality before transplantation. Liver Transpl 2014; 20:1081-1088.
30. Prentis JM, Manas DM, Trenell MI, et al. Submaximal cardiopulmonary exercise testing predicts 90-day survival after liver transplantation. Liver Transpl 2012; 18:152-159.
31. Masuda T, Shirabe K, Ikegami T, et al. Sarcopenia is a prognostic factor in living donor liver transplantation. Liver Transpl 2014; 20:401-407.
32. Durand F, Buyse S, Francoz C, et al. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. J Hepatol 2014; 60:1151-1157.
33. Krell RW, Kaul DR, Martin AR, et al. Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl 2013; 19:1396-1402.
34. Hamaguchi Y, Kaido T, Okumura S, et al. Impact of quality as well as quantity of skeletal muscle on outcomes after liver transplantation. Liver Transpl 2014; 20:1413-1419.
35. Kaido T, Ogawa K, Fujimoto Y, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am J Transplant 2013; 13:1549-1556.
36. Waits SA, Kim EK, TerjimanianMN, et al. Morphometric age and mortality after liver transplant. JAMA Surg 2014; 149:335-340.
37. Montano-Loza AJ, Meza-Junco J, Baracos VE, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl 2014; 20:640-648.
38. Kemmer N, NeffGW, Franco E, et al. Nonalcoholic fatty liver disease epidemic and its implications for liver transplantation. Transplantation 2013; 96:860-862.
39. Rinella ME, Loomba R, Caldwell SH, et al. Controversies in the diagnosis and management of NAFLD and NASH. Gastroenterol Hepatol (N Y) 2014; 10:219-227.
40. Vanwagner LB, Bhave M, Te HS, et al. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology 2012; 56:1741-1750.
41. Wang X, Li J, Riaz DR, et al. Outcomes of liver transplantation for nonalcoholic steatohepatitis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12:394.e1-402.e1.
42. Afzali A, Berry K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 2012; 18:29-37.
43. Wong RJ, Chou C, Bonham CA, et al. Improved survival outcomes in patients with nonalcoholic steatohepatitis and alcoholic liver disease following liver transplantation: An analysis of 2002-2012 United Network for Organ Sharing data. Clin Transplant 2014; 28:713-721.
44. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889-896.
45. Sanchez-Fueyo A, Restrepo JC, Quinto L, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73:56-63.
46. Everson GT, Terrault NA, Lok AS, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57:1752-1762.
47. Picciotto FP, Tritto G, Lanza AG, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46:459-465.
48. Berenguer M, Palau A, Aguilera V, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8:679-687.
49. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study. Gastroenterology 2007; 132:1746-1756.
50. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: An open-label study. Gastroenterology 2015; 148:100-107.
51. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148:108-117.
52. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371:2375-2382.
53. Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for posttransplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014; 46:923-927.
54. Reddy KR, Everson GT, Flamm SL, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. Hepatology 2014; 60:200A-201A.
55. Pungpapong S, Werner KT, Aqel B, et al. Multicenter experience using sofosbuvir and simeprevir with/without ribavirin to treat HCV genotype 1 after liver transplantation. Hepatology 2014; 60(S1):201A.
56. Bzowej NH, Joshi S, Therapondos G, et al. Posttransplant treatment of severe recurrent hepatitis C (HCV) with daclatasvir and sofosbuvir plus or minus ribavirin. Hepatology 2014; 60(S1):543A.
57. Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365:1790-1800.
58. Donckier V, Lucidi V, Gustot T, Moreno C. Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy. J Hepatol 2014; 60:866-871.
59. Testino G, Burra P, Bonino F, et al. Acute alcoholic hepatitis, end stage alcoholic liver disease and liver transplantation: An Italian position statement. World J Gastroenterol 2014; 20:14642-14651.
60. Singal AK, Chaha KS, Rasheed K, Anand BS. Liver transplantation in alcoholic liver disease: current status and controversies. World J Gastroenterol 2013; 19:5953-5963.
61. Northup PG, Intagliata NM, Shah NL, et al. Excess mortality on the liver transplant waiting list: unintended policy consequences and model for End-stage Liver Disease (MELD) inflation. Hepatology 2015; 61:285-291.
62. Wong RJ, Devaki P, Nguyen L, et al. Increased long-term survival among patients with hepatocellular carcinoma after implementation of Model for Endstage Liver Disease score. Clin Gastroenterol Hepatol 2014; 12:1534.e1-1540.e1.
63. Bittermann T, Niu B, HoteitMA, Goldberg D. Waitlist priority for hepatocellular carcinoma beyond Milan criteria: A potentially appropriate decision without a structured approach. Am J Transplant 2014; 14:79-87.
64. Mehta N, Dodge JL, Goel A, et al. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl 2013; 19:1343-1353.
65. Schlansky B, Chen Y, Scott DL, et al. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: A cohort study using the United Network for Organ Sharing registry. Liver Transpl 2014; 20:1045-1056.
66. Samoylova ML, Dodge JL, Yao FY, Roberts JP. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2014; 20:937-944.
67. Halazun KJ, Patzer RE, Rana AA, et al. Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. Hepatology 2014; 60:1957-1962.
68. Chan SC, Sharr WW, Chok KS, et al. Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts. Transplantation 2013; 96:995-999.
69. Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl 2010; 16:925-929.
70. Toso C, Majno P, Berney T, et al. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list. Transpl Int 2014; 27:686-695.
71. Vitale A, Volk ML, De Feo TM, et al. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol 2014; 60:290-297.
72. OPTN Liver and Intestinal Organ Transplantation Committee Forum. Preliminary data analysis on the effect of Share 35-broader regional sharing-in its first year after implementation. ''Share 35'' liver policy: Analysis at 1 year. 2014; Available at: http://transplantpro.org/wp-content/uploads/14-Share-35-Edwards. pdf. [Accessed 1 December 2014]
73. Trotter JF, Arenas JD, Bynon JS, et al. A preliminary analysis of liver allocation based on the ''Share 35'' policy in UNOS region 4. Hepatology 2014; 60(S1):260A-261A.
74. OPTN Liver and Intestinal Organ Transplantation Committee. Proposal for Regional Distribution of Livers for Critically Ill Candidates. 2012; Available at: http://optn.transplant.hrsa.gov/PublicComment/pubcommentPropSub-288. pdf. [Accessed 27 January 2015]
75. Gentry SE, Chow EK, Wickliffe CE, et al. Impact of broader sharing on the transport time for deceased donor livers. Liver Transpl 2014; 20:1237-1243.
76. Asrani SK, Kim WR, Edwards EB, et al. Impact of the center on graft failure after liver transplantation. Liver Transpl 2013; 19:957-964.
77. Schwartz A, Schiano T, Kim-Schluger L, Florman S. Geographic disparity: the dilemma of lower socioeconomic status, multiple listing, and death on the liver transplant waiting list. Clin Transplant 2014; 28:1075-1079.
78. Quillin RC, Wilson GC, Wima K, et al. Neighborhood level effects of socioeconomic status on liver transplant selection and recipient survival. Clin Gastroenterol Hepatol 2014; 12:1934-1941.
79. Mathur AK, Ashby VB, Fuller DS, et al. Variation in access to the liver transplant waiting list in the United States. Transplantation 2014; 98: 94-99.
80. Wong RJ, Ahmed A. Combination of racial/ethnic and etiology/diseasespecific factors is associated with lower survival following liver transplantation in African Americans: An analysis from UNOS/OPTN database. Clin Transplant 2014; 28:755-761.
81. Goldberg DS, French B, Forde KA, et al. Association of distance from a transplant center with access to waitlist placement, receipt of liver transplantation, and survival among US veterans. JAMA 2014; 311:1234-1243.
82. Nadim MK, Sung RS, Davis CL, et al. Simultaneous liver-kidney transplantation summit: current state and future directions. Am J Transplant 2012; 12:2901-2908.
83. Davis CL, Feng S, Sung R, et al. Simultaneous liver-kidney transplantation: evaluation to decision making. Am J Transplant 2007; 7:1702-1709.
84. Hmoud B, Kuo YF, Wiesner RH, Singal AK. Outcomes of liver transplantation alone after listing for simultaneous kidney: comparison to simultaneous liver kidney transplantation. Transplantation 2014. [Epub ahead of print]
85. Brennan TV, Lunsford KE, Vagefi PA, et al. Renal outcomes of simultaneous liver-kidney transplantation compared to liver transplant alone for candidates with renal dysfunction. Clin Transplant 2015; 29:34-43.
86. Chang Y, Gallon L, Jay C, et al. Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy. Liver Transpl 2014; 20:1034-1044.
87. Sterneck M, Kaiser GM, Heyne N, et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant 2014; 14:701-710.
88. Saliba F, De Simone P, Nevens F, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 2013; 13:1734-1745.
89. Alegre C, Jimenez C, Manrique A, et al. Everolimus monotherapy or combined therapy in liver transplantation: indications and results. Transplant Proc 2013; 45:1971-1974.
90. Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT. Am J Transplant 2012; 12:1855-1865.
91. Benitez C, Londono MC, Miquel R, et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 2013; 58:1824-1835.
92. de la Garza RG, Sarobe P, Merino J, et al. Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl 2013; 19:937-944.